SEQ
  • Bienvenido a la SEQ
    • Junta Directiva
    • Misión, visión y valores
    • Elecciones para la renovación Junta Directiva de la SEQ 2021
    • Estatutos SEQ
    • Colaboradores
    • Hazte socio
    • Contacto
  • Noticias
    • Cursos
    • Agenda de Congresos
    • Sociedades Científicas
    • Revistas Científicas
  • Actividades
    • Reuniones
    • Congresos
    • Cursos de Formación
  • Revista Española de Quimiopterapia
    • Journal info
    • Advance articles
    • Search an issue
    • Submission guidelines
    • Submit a manuscript
  • Documentos
    • Documentos de Consenso
    • Libros y monografías
    • Revista Infección y Vacunas
    • Informes
    • Declaraciones
    • Base de Datos
    • Otros
      • Curiosidades
      • Narraciones Infecciosas
  • Click to open the search input field Click to open the search input field Buscar
  • Menú Menú
Abstract, Abstract 2021

Rev Esp Quimioter 2021; 34(4): 269-279

Post-COVID syndrome: A reflection and opinion paper

EMILIO BOUZA, RAFAEL CANTÓN MORENO, PILAR DE LUCAS RAMOS, ALEJANDRA GARCÍA-BOTELLA, ALBERTO GARCÍA-LLEDÓ, JAVIER GÓMEZ-PAVÓN, JUAN GONZÁLEZ DEL CASTILLO, TERESA HERNÁNDEZ-SAMPELAYO, MARI CRUZ MARTÍN-DELGADO, FRANCISCO JAVIER MARTÍN SÁNCHEZ, MANUEL MARTÍNEZ-SELLÉS, JOSÉ MARÍA MOLERO GARCÍA, SANTIAGO MORENO GUILLÉN, FRANCISCO JAVIER RODRÍGUEZ-ARTALEJO, JULIÁN RUIZ-GALIANA, SILVIA DE PABLO
BRÜHLMANN, JESÚS PORTA ETESSAM, MAR SANTOS SEBASTIÁN

Published: 20 April 2021

http://www.doi.org/10.37201/req/023.2021

A high proportion of people who have suffered from COVID-19 report, after recovery from the acute phase of the disease, clinical manifestations, both subjective and objective, that continue beyond 3 weeks or even 3 months after the original clinical disease. There is still no agreed nomenclature to refer to this condition, but perhaps the most commonly used is post-COVID syndrome. The Scientific Committee on COVID of the Madrid College of Physicians (ICOMEM) has discussed this problem with a multidisciplinary approach in which internists,
infectious disease specialists, psychiatrists, pneumologists, surgeons, geriatricians, pediatricians, microbiologists, family physicians and other specialists have participated, trying to gather the existing information and discussing it in the group.
The clinical manifestations are very variable and range from simple fatigue to persistent fibrosing lung lesions with objective alterations of pulmonary function. Post-COVID syndrome seems to be particularly frequent and severe in adults who have required admission to Intensive Care Units and has a peculiar behavior in a very small group of children.
The post-COVID syndrome, which undoubtedly exists, is at first sight not clearly distinguishable from clinical manifestations that which occur after other acute viral diseases and after prolonged stays in ICUs due to other diseases. Therefore, it offers excellent research opportunities to clarify its pathogenesis and possibly that of other related entities.
It is possible that progressively there will be an increased demand for care among the millions of people who have suffered and overcome acute COVID for which the health authorities should design mechanisms for the agile management of care that will possibly require well-coordinated multidisciplinary groups.
This paper, structured in questions on different aspects of the post-COVID syndrome, attempts to stage the current state of this problem.

Rev Esp Quimioter 2021; 34(4): 269-279 [Texto completo PDF]


20 abril, 2021/por Luis Alou
Compartir esta entrada
  • Compartir en Facebook
  • Compartir en X
  • Compartir en LinkedIn
  • Compartir por correo
https://seq.es/wp-content/uploads/2017/10/LOGO-SEQ-800X400.png 0 0 Luis Alou https://seq.es/wp-content/uploads/2017/10/LOGO-SEQ-800X400.png Luis Alou2021-04-20 14:02:262021-07-28 07:36:13Rev Esp Quimioter 2021; 34(4): 269-279

REVISTA ESPAÑOLA DE QUIMIOTERAPIA

  • Journal Info
  • Advance Articles
  • Issues
  • Submission guidelines
  • Submit a manuscript

Contacto

Telf.: 913 94 15 12
Email: [email protected]

Política de privacidad

Aviso Legal
Política de Privacidad
Política de Cookies

Tweets by TwitterDev
© Copyright - Sociedad Española de Quimioterapia - Enfold Theme by Kriesi
  • Link to Facebook
  • Link to X
  • Link to LinkedIn
Link to: Rev Esp Quimioter 2021; 34(4): 269-279 Link to: Rev Esp Quimioter 2021; 34(4): 269-279 Rev Esp Quimioter 2021; 34(4): 269-279 Link to: Rev Esp Quimioter 2021; 34(4): 320-329 Link to: Rev Esp Quimioter 2021; 34(4): 320-329 Rev Esp Quimioter 2021; 34(4): 320-329
Desplazarse hacia arriba Desplazarse hacia arriba Desplazarse hacia arriba

Utilizamos cookies propias y de terceros para garantizar el funcionamiento de la web, medir su uso y mejorar nuestros servicios. Puede aceptar todas las cookies, rechazar las no necesarias o configurar sus preferencias. Política de cookies

Configurar cookies

Necesarias para que la web funcione correctamente. No se pueden desactivar desde este panel.

Ayudan a medir el uso del sitio y mejorar sus contenidos.

Permiten publicidad, medición de campañas o personalización de anuncios.

Guardan preferencias o permiten contenido externo no necesario.